SEC Tracker
Get the app

Omeros OMER

Omeros (OMER) filed its Q3 2025 10-Q quarterly report, providing investors with an update on the company's financial performance and operational status. The filing highlights the company's ongoing efforts to advance its drug development pipeline and commercialize its approved products. As a key periodic report, this 10-Q is crucial for investors to assess Omeros' short-term progress and prospects.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Omeros files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  2. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  3. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025